CPDD 78th Annual Scientific Meeting Program

Monday, June 13, 2016
53 Interactions between alcohol and mephedrone in humans
M. Farré 1,2,3 , E. Papaseit 2,1,3 , C. Pérez-Mañà 2,3 , E. de Souza Fernandes 4 ,
J. F. Mateus 2 , E. Olesti 2,6 , K. Kuypers 4 , E. Theunisen 4 , F. Fonseca 5,3 , M. Torrens 5,3 ,
J. Ramaekers 4 , R. F. de la Torre 2,6 , 1 Clinical Pharmacology, Hospital Universitari Germans
Trias i Pujol-IGTP, Badalona, Spain, 2 Pharmacology, Hospital del Mar Medical Research
Institute-IMIM, Barcelona, Spain, 3 Universitat Autonoma de Barcelona-UAB, Barcelona,
Spain, 4 Faculty of Psychology and Neuroscience, Maastricht University, Maastrich,
Netherlands, 5 Institut de Neuropsiquiatria i Addiccions, Hospital del Mar-IMIM-PSMAR,
Barcelona, Spain, 6 Universitat Pompeu Fabra, Barcelona, Spain
54 Select characteristics of recreational of opioid users undergoing a human abuse potential study
M. D. Smith, L. R. Webster, PRA Health Sciences, Salt Lake City, UT
55 Abuse liability of buprenorphine vs. buprenorphine/naloxone: Importance of absolute amount
J. D. Jones 4 , J. M. Manubay 3 , S. Mogali 4 , V. Metz 1 , S. Comer 4 , 1 Columbia University NYSPI,
New York, NY, 3 Family Medicine/Psychiatry, NYSPI/Columbia University, New York, NY,
4
Division on Substance Abuse, New York State Psychiatric Institute/ Columbia University
College of Physicians and Surgeons, New York, NY
56 Monitoring Internet postings for mentions of an extended-release hydrocodone formulation with
abuse-deterrent properties
A. DeVeaugh-Geiss 1 , H. Chilcoat 1 , P. Coplan 1 , V. Harikrishnan 1 , A. C. Besharat 2 , J. L. Green 2 ,
1
Purdue Pharma LP, Stamford, CT, 2 Denver Health RADARS System, Denver, CO
57 Correlating viscosity and in vitro dissolution to in vivo pharmacokinetic profiles of proprietary
injected-molded tablet formulations with abuse-deterrent characteristics
T. Elhauge, N. Skak, M. J. Øvergård, K. Lindhardt, Egalet Corporation, Værløse, Denmark
58 Moderate TBI increases susceptibility to rewarding effects of a subthreshold dose of cocaine in
mice
L. Cannella 1 , S. Merkel 1,2 , R. Razmpour 1 , C. S. Tallarida 2,3 , S. Rawls 2,3 , S. Ramirez 1,2,4 ,
1
Pathology, TUSM, Philadelphia, PA, 2 CSAR, TUSM, Philadelphia, PA, 3 Pharmacology,
TUSM, Philadelphia, PA, 4 Shriner’s, Philadelphia, PA
59 Evaluation of human abuse liability of JZP-110
L. P. Carter 1,5 , E. Sellers 2 , J. Henningfield 3,6 , G. Wang 1 , Y. Lu 1 , D. Kelsh 4 , B. Vince 4 , 1 Jazz
Pharmaceuticals, Palo Alto, CA, 2 University of Toronto, Toronto, ON, Canada, 3 Pinney
Associates, Bethesda, MD, 4 Vince & Associates Clinical Research, Overland Park, KS,
5
University of Arkansas for Medical Sciences, Little Rock, AR, 6 Johns Hopkins School of
Medicine, Baltimore, MD
ETHIC DIFFERENCES/HEALTH DISPARITIES
60 A mixed methods assessment of familism’s (Familismo) influence on the initiation, cessation,
and treatment of injection heroin use
D. V. Flores 1 , L. Torres 1 , J. Burnett 3 , R. Xia 3 , P. Bordnick 1 , 1 University of Houston,
Houston, TX, 3 University of Texas Medical School, Houston, TX
61 A multi-component brief intervention for risky drug use among Latino patients of a federally
qualified health center in East Los Angeles: A randomized controlled trial of the QUIT Using
Drugs Intervention Trial (QUIT) brief intervention
L. Gelberg 1 , R. Andersen 1 , M. Vahidi 1 , M. Rico 1 , S. Baumeister, 2 , B. Leake 1 , 1 UCLA,
Los Angeles, CA, 2 University of Regensburg, Regensburg, Germany
17